Impacts__O on__O commerce:__O Sarissa__B-LOC was__O founded__O in__O 2002__O as__O a__O spinout__O from__O the__O University__B-ORG of__I-ORG Warwick,__I-ORG and__O began__O commercial__O operations__O in__O 2004.__O
The__O underpinning__O research__O has__O led__O to__O 2__O patent__O families__O being__O awarded__O to__O the__O University__B-ORG of__I-ORG Warwick7-9__I-ORG and__O licensed__O to__O Sarissa.__B-LOC
In__O 2012,__O Sarissa__B-ORG applied__O for__O its__O first__O patent__O to__O cover__O biosensor__O arrays__O (SMARTCap)__B-ORG for__O diagnostic__O use10.__O
Sarissa's__B-MISC biosensors__O have__O international__O commercial__O impact__O as__O evidenced__O by__O US__B-ORG Investigators__I-ORG who__O have__O used__O Sarissa's__O biosensors__O to__O provide__O underpinning__O evidence__O in__O three__O US__B-LOC patent__O applications:__O US20100284984,__O US20100165634,__O WO2013049725.__O
In__O addition__O to__O investment__O income__O from__O two__O venture__O capital__O sourcesA,__O Sarissa__B-ORG has__O raised__O grants__O from__O Advantage__B-LOC West__I-LOC Midlands__I-LOC 2010__O to__O develop__O a__O prototype__O clinical__O device__O for__O measuring__O analytes__O in__O whole__O blood__O -__O the__O SMARTCap;__B-ORG and__O was__O an__O SME__O partner__O in__O an__O FP6__B-MISC consortium__O called__O SANTS__B-ORG (2006-2009,__O http://www.sants-nanosilicates.com/)__O providing__O its__O expertise,__O exemplified__O in__O refs__O 2,3,7-9,__O in__O silicate__O fabrication__O methods__O to__O the__O consortium.__O
Further__O successful__O grant__O funding__O to__O develop__O and__O evaluate,__O in__O substantial__O clinical__O trials,__O new__O clinical__O devices__O based__O on__O the__O IP__B-MISC generated__O from__O the__O underlying__O research__O has__O followed.__O
In__O 2013,__O Dale__B-ORG and__I-ORG Sarissa__I-ORG were__O the__O lead__O applicants__O in__O a__O successful__O bid__O to__O the__O National__B-ORG Institute__I-ORG of__I-ORG Health__I-ORG Research__I-ORG (NIHR)__I-ORG for__O an__O Invention__O for__O Innovation__B-ORG (i4i)__I-ORG Product__I-ORG Development__I-ORG Award__O for__O &#163;575k__O entitled__O "SMARTChip:__O a__O field-deployable__O blood__O test__O for__O stroke,__O capable__O of__O detecting__O brain__O ischaemia__O from__O the__O earliest__O stages__O of__O pathology".__O
Employment:__B-PER Sarissa__I-PER has__O continually__O employed__O at__O least__O one__O person__O since__O 2004__O and__O more__O during__O externally__O funded__O special__O projects.__O
In__O addition,__O it__O employs__O external__O UK-based__B-ORG consultants__O for__O accountancy__O and__O business__O development,__O creating__O a__O total__O of__O 13.3__O FTE__B-ORG since__O 2004.__O
Economy:__O The__O company__O had__O a__O turnover__O of__O &#163;83k__O in__O 2012,__O up__O from__O &#163;62k__O in__O 2008,__O generated__O mainly__O from__O sales__O into__O the__O preclinical__O scientific__O communitiesB.__O
Business__O sector:__O Sarissa__B-PER is__O currently__O working__O with__O scientists__O and__O clinicians__O to__O investigate__O and__O promote__O the__O adoption__O of__O their__O biosensor__O technology__O for__O diagnostic__O purposes.__O
They__O provide__O workshops__O with__O hands-on__O demonstrations,__O external__O demonstrators__O (from__O Europe__B-LOC and__O USA)__B-ORG and__O speakers__O (from__O UK__B-LOC and__O USA)__B-ORG to__O inform__O customers__O and__O potential__O users__O about__O the__O technology.__O
The__O fourth__O workshop__O was__O held__O April__O 15th__O 2013.__O
All__O workshops__O have__O attracted__O delegates__O from__O the__O UK__B-LOC and__O overseas__O (Europe,__B-ORG Canada,__I-ORG US),__I-ORG including__O researchers__O and__O representatives__O from__O the__O pharma__O industry,__O as__O well__O as__O other__O biotech__O SMEs__B-ORG interested__O in__O the__O technology.__O
The__O workshops__O provide__O excellent__O networking,__O marketing__O opportunities__O and__O have__O resulted__O in__O new__O customers__O adopting__O the__O biosensors,__O including__O customers__O from__O the__O Pharma__B-ORG sector.__O
The__O current__O product__O range__O is__O the__O most__O complete__O in__O the__O world__O and__O provides__O microelectrode__O biosensors__O for__O ten__O different__O analytes.__O
Sarissa__B-PER sells__O to__O researchers__O in__O the__O USA,__B-ORG Canada,__I-ORG Japan,__I-ORG Europe,__I-ORG and__O the__O UK.__B-LOC
These__O buyers__O include__O research__O groups__O in__O universities__O and__O increasing__O sales__O (10%__O of__O total__O sales__O in__O 2012)__O into__O non-academic__O sectors:__O the__O pharma__O industry__O and__O US__B-LOC government__O agencies__O (FDA)B.__B-ORG Impacts__I-ORG on__O healthcare,__O practitioners__O and__O patient__O services:__O Arising__O from__O the__O characterization__O of__O the__O RP__B-ORG biosensors3,8,__O and__O the__O use__O of__O biosensors__O to__O measure__O release__O of__O purines__O during__O ischaemia5,__O Dale__B-ORG and__O Sarissa__B-ORG are__O the__O lead__O investigators,__O in__O collaboration__O with__O two__O NHS__B-ORG Trusts__I-ORG (University__I-ORG Hospitals__I-ORG of__I-ORG Coventry__I-ORG &amp;__O Warwickshire__B-ORG (UHCW),__O and__O University__B-LOC Hospital__I-LOC of__I-LOC North__I-LOC Staffs__I-LOC (UHNS)),__I-LOC in__O the__O first__O clinical__O trials__O of__O the__O RP-coated__O purine__O biosensors__O for__O the__O diagnosis__O of__O stroke__O (funded__O by__O NIHR).__B-ORG
This__O area__O of__O innovation__O is__O seen__O as__O a__O key__O area__O for__O the__O NHS,__B-MISC as__O stroke__O costs__O the__O NHS__B-MISC some__O &#163;7bn__B-MISC annually,__O and__O there__O are__O roughly__O 150,000__O stroke__O incidents__O per__O year.__O
The__O technology__O invented__O by__O Sarissa__B-ORG provides__O an__O extremely__O rapid__O measurement__O (minutes)__O of__O an__O analyte__O (the__O purines)__O that__O is__O produced__O within__O minutes__O of__O the__O onset__O of__O stroke__O symptoms.__O
This__O test__O has__O the__O prospect__O of__O greatly__O speeding__O diagnosis,__O enabling__O more__O patients__O to__O receive__O thrombolysis__O and__O reducing__O time__O from__O diagnosis__O to__O onset__O of__O treatment.__O
Every__O minute__O saved__O by__O Sarissa's__B-MISC technology__O will__O improve__O patient__O outcomes__O and__O reduce__O the__O annual__O cost__O of__O stroke__O treatment__O to__O the__O NHS;__B-ORG even__O modest__O improvements__O resulting__O from__O application__O of__O Sarissa's__B-LOC technology__O would__O give__O very__O substantial__O absolute__O savings.__O
A__O clinician__O from__O UHNS__B-ORG verified__O that__O "This__B-ORG technology__O has__O the__O potential__O to__O improve__O treatment__O rates__O and__O outcome__O for__O stroke__O patients__O nationally__O and__O worldwide.__O
This__O has__O been__O recognised__O by__O the__O Acute__B-ORG Clinical__I-ORG Studies__I-ORG Group__O of__O the__O Stroke__B-ORG Research__I-ORG Network,__I-ORG who__O encouraged__O and__O supported__O Professor__B-ORG Dale__I-ORG to__O develop__O this__O into__O the__O now__O successful__O application__O for__O an__O i4i__O grant".C__O The__O development__O and__O characterization__O of__O the__O RP__B-ORG biosensors3,7-10__O has__O led__O to__O adoption__O of__O this__O technology__O by__O clinicians__O in__O patient__O research.__O
Prof__B-PER Chris__I-PER Imray,__I-PER a__O Consultant__O Vascular__B-PER Surgeon__I-PER at__O UHCW__B-ORG has__O been__O using__O Sarissa's__O biosensors__O during__O surgery__O to__O monitor__O brain__O ischaemia__O (2012-2013).__O
Very__O exciting__O results__O suggest__O that__O the__O preoperative__O level__O of__O blood__O purines__O may__O allow__O better__O prioritization__O of__O patients__O at__O risk__O of__O stroke__O and__O transient__O ischaemic__O attack.__O
Dr__O Gareth__B-PER Ackland,__I-PER a__O Consultant__B-ORG Anaesthetist__I-ORG and__I-ORG Research__I-ORG Fellow__I-ORG from__I-ORG University__I-ORG College__I-ORG Hospital,__I-ORG LondonD,__I-ORG has__O used__O Sarissa's__O biosensors__O with__O blood__O samples__O from__O patients__O suffering__O from__O sepsis__O and__O surgical__O trauma__O (2013).__O
His__O collaboration__O with__O Sarissa__B-PER is__O developing__O proof-of-principle__O evidence__O that__O underpins__O new__O IP__O jointly__O created__O with__O UCL__B-ORG to__O develop__O bedside__O diagnostics__O of__O sepsis__O and__O trauma,__O to__O be__O exclusively__O licenced__O to__O Sarissa.__B-LOC
"Dale's__O work__O has__O enabled__O the__O development__O of__O novel__O modes__O of__O detection__O of__O inflammation__O and__O how__O this__O may__O be__O managed__O clinically__O in__O real-time"D.__O The__O potential__O market__O for__O sepsis/trauma__O diagnostics__O is__O probably__O an__O order__O of__O magnitude__O bigger__O than__O the__O stroke__O market.__O
Industrial__O collaborations:__O A__O collaboration__O agreement__O is__O in__O place__O with__O Pinnacle__B-ORG Technologies__I-ORG Inc,__I-ORG USAE,__I-ORG in__O which__O Sarissa__B-LOC uses__O its__O methods__O to__O coat__O their__O sensor__O assemblies.__O
This__O has__O allowed__O Pinnacle__O to__O offer__O a__O wider__O range__O of__O biosensors,__O and__O Sarissa__O to__O offer__O biosensors__O in__O a__O format__O suitable__O for__O chronic__O in__O vivo__O recordings.__O
Approximately__O 10%__O of__O Sarissa's__B-ORG product__O sales__O now__O involve__O biosensors__O made__O on__O the__O Pinnacle__B-LOC Technologies'__I-LOC assemblies.__O
Between__O 2004__O and__O 2010,__O Sarissa__B-ORG provided__O business__O to__O Sycopel__B-ORG International__I-ORG Ltd__I-ORG by__O subcontracting__O them__O to__O make__O microelectrode__O biosensor__O assemblies,__O which__O Sarissa__B-ORG then__O coated__O with__O a__O sol-gel__O biolayer__O to__O make__O a__O fully__O functional__O biosensor.__O
Sycopel__O also__O generated__O further__O sales__O through__O manufacture,__O to__O our__O specification,__O of__O a__O dual__O potentiostat,__O an__O essential__O instrument__O required__O for__O making__O the__O biosensor__O measurements.__O
This__O provided__O to__O Sarissa's__B-MISC customers__O suitable__O instrumentation__O for__O use__O with__O the__O microelectrode__O biosensors__O and__O assisted__O dissemination__O and__O uptake__O of__O the__O technology.__O
In__O 2010,__O Sarissa__B-ORG bought__O the__O rights__O from__O Sycopel__O to__O take__O fabrication__O of__O biosensor__O assemblies__O in-house,__O using__O their__O jigs__O and__O methods.__O
Collaboration__O is__O now__O underway__O with__O another__O SME,__O Whistonbrook__B-PER TechnologiesF.__I-PER
Whistonbrook__O is__O subcontracted__O by__O Sarissa__O to__O develop__O two__O instruments__O for__O clinical__O use__O in__O the__O NIHR__B-MISC i4i__O project:__O one__O for__O the__O SMARTCap__B-ORG device__O and__O a__O second__O instrument__O for__O use__O with__O the__O field-deployable__O SMARTChip__B-ORG device.__O
In__O addition__O Whistonbrook__B-MISC has__O designed__O a__O further__O dual__O potentiostat__O for__O the__O non-clinical__O customers__O who__O use__O Sarissa's__B-PER sensors.__O
These__O subcontracts__O support__O the__O development__O costs__O of__O the__O instruments__O and__O will__O ultimately__O give__O Whistonbrook__B-ORG further__O sales.__O
